Atuka：2025年优化帕金森疾病治疗药物的临床前研究白皮书（英文版）

A reliable, high-quality preclinical package is designed to assess the potential benefit of a new therapeutic, and minimize translational risk before it proceeds to costly and time-consuming clinical trials. It’s precisely in this assessment of efficacy, however, where too many preclinical studies come up short. Often, it’s clear that a drug has some potential value in treating a disease, but not necessarily so clear how that value can be realized. While the FDA assesses approvals for a